Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423241 · ClinicalTrials.gov registry record · NA
SEMPERFLO* Pain Management System in Inguinal Hernia Repair
A NA study, sponsored by Ethicon.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00423241 is a NA study that was terminated before completion, run by Ethicon. The registered enrollment target is 7 participants.
The verdict
NCT00423241, a NA study, was terminated before completion, sponsored by Ethicon.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will compare the clinical performance of the SEMPERFLO\* Pain Management System with another commercial pain relief system using 0.5% bupivacaine following unilateral, open, inguinal hernia repair procedures. \*Trademark
Interventions
- DEVICE SEMPERFLO Pain Management System
- DEVICE ON-Q PainBuster Post-Op Pain Relief System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423241
The ClinicalTrials.gov registry entry for NCT00423241 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ethicon, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SEMPERFLO Pain Management System is the first listed.
NCT00423241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423241 about?
NCT00423241 is a clinical study titled "SEMPERFLO* Pain Management System in Inguinal Hernia Repair". This study will compare the clinical performance of the SEMPERFLO\* Pain Management System with another commercial pain relief system using 0.5% bupivacaine following unilateral, open, inguinal hernia repair procedures. \*Trademark
What is the current status of trial NCT00423241?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2007-01. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00423241?
The interventions under investigation include: SEMPERFLO Pain Management System (DEVICE), ON-Q PainBuster Post-Op Pain Relief System (DEVICE).
Who is sponsoring clinical trial NCT00423241?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.